Standigm
AI-powered drug discovery and repurposing from Seoul
Standigm is a South Korean AI drug discovery company whose ASK platform (AI-based Standigm Knowledge) integrates knowledge graph analysis, molecular generation, and predictive modeling for target identification, hit discovery, and drug repurposing. The company has partnerships with global pharmaceutical companies including Sanofi and SK Biopharmaceuticals, and has filed multiple IND applications.
Target Discovery, Generative Chemistry, Virtual Screening
ASK
Technology
ASK (AI-based Standigm Knowledge) platform integrates knowledge graph analysis for target identification, generative molecular design for hit discovery, and predictive modeling for ADMET and efficacy optimization. The platform supports both novel drug discovery and repurposing of existing drugs.
Partnerships
Similar companies
Insilico Medicine
First AI-discovered and AI-designed drug in Phase 2 clinical trials
clinical · 2014Genesis Therapeutics
AI precision drug discovery for undruggable targets
preclinical · 2019Atomwise
AI-powered virtual screening for small molecule drug discovery
preclinical · 2012BenevolentAI
AI-enabled knowledge graph for drug discovery and repurposing
clinical · 2014Get updates on Standigm
We'll notify you when we publish updates about Standigm.